VANCOUVER, British Columbia, Aug. 1, 2003 (PRIMEZONE) -- ProtoKinetix, Incorporated (OTCBB:RJVN) (OTCBB:PKTX) announced today that, as of the opening bell, Monday, August 4, 2003, it will trade on the over the counter market under the new ticker symbol PKTX.
Commenting on the new ticker symbol is ProtoKinetix's President and Director, Dr. John Todd: "While the focus of my efforts is on furthering our world class cancer-fighting initiatives and continuing to add real value for our shareholders, the Board of Directors felt that it was imperative that we change the name of the Company as well as our stock ticker symbol in order to more accurately reflect the true nature of the Company's business."
Dr. Todd added, "Some weeks back, we amended our articles of incorporation and changed the name of the Company to ProtoKinetix. We also made an application to Nasdaq to change our stock symbol. Today, we received word from Nasdaq and our corporate counsel that our application to change our symbol was received and approved. Nasdaq has assigned us the ticker symbol PKTX."
The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Some information included in this press release contains statements that are forward-looking. Such forward-looking information involves significant risks and uncertainties that could affect anticipated results in the future and, accordingly, these results may differ materially from those expressed in any forward-looking statements made by or on behalf of the Company. For a description of additional risks and uncertainties, please refer to the Company's filings with the Securities and Exchange Commission. Specifically, investors should be cautious as ProtoKinetix, Incorporated is presently an underfunded, undercapitalized development stage biotechnology company. This presents tremendous risk to investors and existing and prospective investors should undertake a thorough due diligence process, as well as seek advice from a registered securities broker before considering an investment in this company.